Redeye comments on Freemelt’s agreement with WEAREAM, which marks an important step in the ongoing c...
Redeye is now more optimistic on the near-term outlook following an array of orders from RemaSawco’s...
Redeye updates on Better Collective following the announcement of preliminary results for 2023 which...
Redeye retains its positive view of Sdiptech following a Q4 report that was largely in-line with ou...
Lower sales offset by margins as operational measures take effect EPS estimates largely intact due t...
Redeye takes a more positive view towards Hexatronic following a relative to expectations solid Q4 r...
Q4 NOI margin on the softer side 80% floating debt drives estimate revisions 2024e P/CEPS of ~20.
Fruitful restructuring - we revisit the Careium story Double-digit organic growth to persist in '24e...
Organic earnings under pressure, but solid M&A '24e-'25e adj.
Redeye comments on Episurf Medical’s Q4 report and notes important key activities carried out in the...
Redeye updates its estimates after Sleep Cycle’s Q4 2023 report, which came in slightly lower on sal...
Growth remains soft while we wait for new releases EBIT ests.
Redeye comments on Better Collective’s announcement of preliminary 2023 revenue and EBITDA which are...
Fortsatt press på den organiska tillväxten… Med en kombination av accelererande nedstängning av kopp...
Redeye endorses yesterday's promising effect signal in 6 out of 8 patients followed for at least 3 m...
Redeye sees only minor deviations in the Q4 numbers vs our expectations.
Innofactor’s Q4 was in line with expectations. Continued uncertainty reduces visibility going into 2...
The outlook for 2024 looks brighter after the tough 2023.
Redeye states that the report was below expectations on sales and profit.
Sales235m (-19% vs. ABGSCe), adj. EBITA 16m (-14% vs.
